Research programme: antibody therapeutics - Merck/Teijin Pharma

Drug Profile

Research programme: antibody therapeutics - Merck/Teijin Pharma

Alternative Names: anti-tau inhibitors - Merck/Teijin Pharma

Latest Information Update: 14 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co; Teijin Pharma
  • Class Antibodies; Monoclonal antibodies
  • Mechanism of Action Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 25 May 2017 Merck and Teijin Pharma agree to co-develop and co-promote anti-tau inhibitors for Alzheimer's disease
  • 25 May 2017 Preclinical trials in Alzheimer's disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top